MMIT - Managed Markets Insight & Technology

  • Home
  • MMIT - Managed Markets Insight & Technology

MMIT - Managed Markets Insight & Technology We leverage technology, research and industry experts to make sense of how and why specific pharmaceutical drugs are covered.

08/09/2026

Missing plan-level data? MMIT matches your patient tokens to our verified repository and appends accurate plan attributes you can actually trust.

Match patients across datasets without direct PHI exchange. Learn how MMIT solves patient plan detail challenges: https://vist.ly/5hqra

08/09/2026

According to our research, 51% of pharma execs say AI-enabled prior authorization automation is significantly impacting or reshaping their brands. As payers remove the human touchpoints that once allowed for physician advocacy and appeal, the pressure on manufacturers is only growing.

Learn how pharma is responding in this new infographic. https://vist.ly/5hpvr

08/09/2026

Last chance to register! The MMIT Executive Forum is coming to Grounds for Sculpture in Hamilton, NJ, on Sept. 16 — and it's an experience you won't want to miss.

Hear from keynote speaker Jayne Hornung, MMIT's Chief Clinical Officer, alongside speakers from Abbott, Neurelis, Springworks Therapeutics, and more. And the best part? It's complimentary for MMIT clients. Space is limited.

RSVP today: https://vist.ly/5hnnc

07/09/2026

AbbVie navigated roughly $16B in U.S. Humira erosion. The lesson for every immunology manufacturer facing a biosimilar clock: build the successor before the cliff, not after it.

MMIT's Q2 2026 immunology deep dive explores what manufacturers can learn from this transition, including why 51% of payers expect a more restrictive strategy moving forward.

Learn what it takes to stay ahead of the biosimilar cliff and evolving payer demands: https://vist.ly/5hk64

04/09/2026

83% of vertically integrated payers say integration has been extremely impactful on rebate and contract ex*****on.

That's a fundamental shift in who manufacturers are actually negotiating with. When a single consolidated entity controls the PBM, specialty pharmacy, and formulary strategy, the entire approach to biosimilar market access has to change.

MMIT's latest biosimilar research explains what that means for manufacturers. https://vist.ly/5hbmh

04/09/2026

RSVP TODAY: Market access is changing faster than ever. But what do these changes actually mean for your team?

That's exactly what we'll be exploring at the MMIT Executive Forum on Sept. 16 at Grounds for Sculpture in Hamilton, NJ.

At this one-day-only event, you'll hear from keynote speaker Jayne Hornung, along with speakers from across the industry on:

→ The evolving state of patient access
→ The role of AI in commercialization
→ What it takes to stay ahead

This event is complimentary for MMIT clients.

RSVP and get the details: https://vist.ly/5h9vu

03/09/2026

One of the biggest challenges in market access is knowing which accounts to prioritize.

Understanding formulary coverage, clinical pathways, and contracting dynamics across IDNs helps field teams target accounts with the greatest opportunity.

In this use case, learn how one pharma company transformed IDN insights into measurable utilization gains: https://vist.ly/5h7qm

03/09/2026

Medical drug claims are complicated enough. Your data shouldn’t add to the equation.

ReimbursementCodes brings specialty drug pricing, coding, and clinical data together in one normalized, integration-ready dataset, helping teams connect the codes, validate the numbers, and support more accurate reimbursement. Less data wrangling. More reimbursement clarity.

Explore ReimbursementCodes and turn complex data into reimbursement certainty. https://vist.ly/5h59b

03/09/2026

One day. 9:30 to 4:30. The people shaping where market access goes next.

The MMIT Executive Forum lands Wednesday, Sept. 16 at Grounds for Sculpture in Hamilton, NJ, and it's designed for the conversations you can't have over email.

→ Keynote: Jayne Hornung, MMIT Chief Clinical Officer
→ Insights from Abbott, Neurelis, Springworks Therapeutics, and more
→ Peer networking, idea exchange, and emerging best practices
→ Breakfast, lunch, and happy hour catered on-site — plus time to explore the gardens

It's complimentary for MMIT clients. RSVP today.

Save your seat: https://vist.ly/5h595

02/09/2026

AI is reshaping how market access strategies get built. The question is whether your team is ready to use it.

At the MMIT Executive Forum on Wednesday, September 16, you'll learn how your peers are applying AI to reshape their market access strategies, redefine success metrics, and influence decision-making across their organizations.

You'll also get a first look at how MMIT is approaching innovation and applying AI — plus a keynote from , MMIT's Chief Clinical Officer, on the state of patient access today.

It’ll be at the Grounds for Sculpture, Hamilton, NJ, and is complimentary for MMIT clients.

Register: https://vist.ly/5gysr

Address


Telephone

+12677513162

Website

Alerts

Be the first to know and let us send you an email when MMIT - Managed Markets Insight & Technology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to MMIT - Managed Markets Insight & Technology:

Shortcuts

  • Want your practice to be the top-listed Clinic?

Share